Inferra AI / Company / AUPH / Slides
Aurinia Pharmaceuticals — Download Corporate Presentation (company IR deck)
Aurinia Pharmaceuticals (AUPH) · 0 slides · Filed Oct 30, 2026
Every slide of this earnings presentation, with the text as published. Open the original deck ↗ · All AUPH deck slides
Slide 1 — Corporate Presentation
® Corporate Presentation October 2026
Slide 2 — Forward-Looking Statements
® Forward-Looking Statements This presentation contains forward-looking statements within the meaning of applicable U.S. securities law and forward-looking information within the meaning of applicable Canadian securities law. We caution investors that forward-looking statements are based on management’s expectations and assumptions as of the date of this presentation and involve substantial risks and uncertainties that could cause the actual outcomes to differ materially from what we currently expect. These risks and uncertainties include, but are not limited to, those associated with: total revenue; net product sales; the timing, design and results of clinical studies; and other risks and uncertainties identified in our filings with the U.S. Securities and Exchange Commission. Forward-looking statements in this presentation apply only as of the date made and we undertake no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances. Additional information related to Aurinia, including a detailed list of the risks and uncertainties affecting Aurinia and its business, can be found in Aurinia’s most recent Annual Report on Form 10-K and its other public filings available by accessing the Canadian Securities Administrators’ System for Electronic Document Analysis and Retrieval (SEDAR) website at www.sedarplus.ca or the U.S. Securities and Exchange Commission’s Electronic Document Gathering and Retrieval System (EDGAR) website at www.sec.gov/edgar, and on Aurinia’s website at www.auriniapharma.com. 2
Slide 3 — Changing the
® Changing the Trajectory of Autoimmune Diseases Accelerate LUPKYNIS® commercialization by improving screening, diagnosis and treatment rates Continue LUPKYNIS commercial growth Advance AUR200 development program Accelerate LUPKYNIS® commercialization by improving screening, diagnosis and treatment rates Advance aritinercept development 3
Slide 4 — Recent Financial
® Recent Financial Results
Slide 5 — Results for the Nine Months Ended September 30
® Results for the Nine Months Ended September 30 5 Nine Months Ended September 30 % Change 2026 2025 Total Revenue $244.6 million $205.9 million 19% Net Product Sales $232.4 million $197.2 million 18% Net Income $103.5 million $76.4 million 35% Diluted Earnings per Share $0.76 $0.55 38% Cash Flows from Operating Activities $131.5 million $90.0 million 46%
Slide 6 — 2026 Financial Guidance
® Net Product Sales 2021 2022 2023 2024 2025 $45.5M $103.5M $158.5M $216.2M $271.3M 2026 Financial Guidance 6 Initial Guidance Range Current Guidance Range a Total Revenue $315 million to $325 million $325 million to $330 million Net Product Sales $305 million to $315 million $310 million to $315 million a Guidance as of October 30, 2026 $310.0M $315.0M 2026 Guidance Range a
Slide 7 — LUPKYNIS®
® LUPKYNIS® A calcineurin inhibitor (CNI) indicated in combination with a background immunosuppressive regimen for the treatment of adult patients with active lupus nephritis The first oral therapy approved for the treatment of lupus nephritis
Slide 8 — Lupus Nephritis (LN) Is Among the Most Severe and Dangerous
® • SLE, commonly known as lupus, is a chronic autoimmune disease where the body's immune system mistakenly attacks its own healthy tissues and organs • Over 200,000 people in the United States are estimated to have SLE a, of which 20% to 60% develop LN b Lupus Nephritis (LN) Is Among the Most Severe and Dangerous Complications of Systemic Lupus Erythematosus (SLE) LN occurs when the immune system attacks the kidneys SLE/LN disproportionately affects women and people of color a Measuring proteinuria (protein in the urine) is critical for monitoring disease activity and response to therapy c Inflammation leads to blood and protein in the urine, impaired kidney function and even kidney failure Kidney Glomerulo- nephritis a U.S. Centers for Disease Control and Prevention 2024 b KDIGO Lupus Nephritis Work Group, Kidney Int 2024 c Tamirou et al., Ann Rheum Dis 2016 8
Slide 9 — Proteinuria Reduction Is Associated with Long-Term Renal Preservation
® Proteinuria Reduction Is Associated with Long-Term Renal Preservation Kidney Survival Based on Proteinuria Response Status a, b ESKD=end-stage kidney disease a Adapted with permission from Chen et al., Clin J Am Soc Nephro 2008 b Retrospective analysis of patients (N=86) enrolled in the prospective, controlled study of plasmapheresis in severe LN to determine long-term prognosis of achieving partial response. Complete response was defined as SCr ≤1.4 mg/dL and proteinuria ≤0.33 g/day within 5 years of study entry, and partial response was defined as ≤25% increase in baseline SCr and ≥50% reduction in baseline proteinuria to ≤1.5 g/day (but >0.33 g/day) within 5 years of entering the study. Kidney survival was determined by kidney failure (≥6 mg/dL SCr or the initiation of kidney replacement therapy). 9 The larger the initial reduction in proteinuria in the first several months of management, the lower the risk of ESKD
Slide 10 — 2024 ACR LN Treatment Guideline Emphasizes Early and Aggressive
® Goal is complete renal response, including reduction in proteinuria to ≤0.5 mg/mg within 6-12 months • Specifically, this updated guideline now details the following: Triple immunosuppressive therapy, including a calcineurin inhibitor (CNI) or belimumab as first-line therapy LUPKYNIS is the only CNI that is FDA approved for LN 10 a 2024 ACR Guideline for the Screening, Treatment, and Management of Lupus Nephritis: Guideline Summary 2024 Reduce corticosteroid dose to minimize toxicity, with a goal of ≤5 mg/day by 6 months of therapy 2024 ACR LN Treatment Guideline Emphasizes Early and Aggressive Treatment to Preserve Kidney Function a
Slide 11 — LUPKYNIS Is a Novel, Structurally Modified CNI that Targets LN with
® LUPKYNIS Is a Novel, Structurally Modified CNI that Targets LN with a Dual Mechanism of Action 11 T CELL CONTROL Immune Modulation PODOCYTE SUPPORT Kidney Filter Protection DUAL MECHANISM Inhibits IL-2 mediated T cell activation and IFN-γ mediated inflammatory response Stabilizes podocyte structure
Slide 12 — Robust Clinical Study History
® AURA-LV Randomized Phase 2 Study in 265 Patients AURORA 1 Randomized Phase 3 Study in 357 Patients AURORA 2 Randomized Extension Study in 216 Patients Robust Clinical Study History 12 Improved Complete Renal Response Rate Established Safety Profile Rapid Proteinuria Reduction
Slide 13 — 81%
® Significantly More Patients on LUPKYNIS Achieved a Complete Renal Response in AURORA 1 as Early as Week 24 a 40.8% (73/179) 22.5% (40/178) 0 10 20 30 40 50 60 70 80 90 100 LUPKYNIS + MMF + Corticosteroids Placebo + MMF + Corticosteroids Patients Achieving Complete Renal Response at Week 52, % Complete Renal Response at Week 52 (Primary Endpoint; p<0.001) b 81% more likely Patients treated with LUPKYNIS were 81% more likely to achieve CRR at week 52 than those on MMF + corticosteroids alone 32.4% (58/179) 19.7% (35/178) 0 10 20 30 40 50 60 70 80 90 100 LUPKYNIS + MMF + Corticosteroids Placebo + MMF + Corticosteroids Patients Achieving Complete Renal Response at Week 24, % Complete Renal Response at Week 24 (Secondary Endpoint; p=0.002) b 64% more likely Patients treated with LUPKYNIS were 64% more likely to achieve CRR at week 24 than those on MMF + corticosteroids alone a Rovin et al., Lancet 2021 b CRR was defined as urine protein-to-creatine ratio (UPCR) of ≤0.5 mg/mg, stable renal function (defined as eGFR ≥60 mL/min/1.73 m2 or no confirmed decrease from baseline in eGFR of >20%), no sustained corticosteroids and no administration of rescue medications 13
Slide 14 — LUPKYNIS Rapidly Reduced Proteinuria in Fewer Days in AURORA 1 a
® LUPKYNIS Rapidly Reduced Proteinuria in Fewer Days in AURORA 1 a 169 days 372 days 0 50 100 150 200 250 300 350 400 LUPKYNIS + MMF + Corticosteroids (n=179) Placebo + MMF + Corticosteroids (n=178) Days, median UPCR ≤0.5 mg/mg in <6 Months b 29 days 63 days 0 10 20 30 40 50 60 70 LUPKYNIS + MMF + Corticosteroids (n=179) Placebo + MMF + Corticosteroids (n=178) Days, median 50% UPCR Reduction in 29 Days b a Rovin et al., Lancet 2021 b Secondary endpoint LUPKYNIS in combination with MMF and corticosteroids reduced proteinuria twice as fast as MMF and corticosteroids alone 203 fewer days 34 fewer days 14
Slide 15 — New Analysis (EULAR 2026) a Shows LUPKYNIS Associated with 53%
® 15 a Saxena et al., EULAR 2026 b Time to renal-related event or death is defined as the time to the first occurrence of death, treatment failure, worsening proteinuria or worsening eGFR New Analysis (EULAR 2026) a Shows LUPKYNIS Associated with 53% Reduction in Risk of Renal-Related Event or Death Time to Renal-Related Event or Death b (AURORA 1 Phase 3 Population) Probability of Event (%) 50 45 40 35 30 25 20 15 10 5 0 0 13 26 39 52 65 Time from First Dose (Weeks) Treatment Events (%) HR (95% CI) P-value LUPKYNIS 28 (15.7) 0.467 (0.296, 0.736) 0.0007 Placebo 55 (30.9) LUPKYNIS 0.0 [178] 7.3 [164] 11.3 [154] 14.8 [142] 16.0 [117] 16.0 [2] Placebo 0.0 [178] 11.8 [154] 22.8 [132] 27.5 [121] 31.1 [89] Probability [N at Risk]: LUPKYNIS Placebo Censored
Slide 16 — Adverse Reactions Occurring in ≥3% of Patients Treated with
® Adverse Reactions Occurring in ≥3% of Patients Treated with LUPKYNIS 23.7 mg Twice a Day and ≥2% Higher than Placebo in AURORA 1 and AURA-LV a Adverse Reaction LUPKYNIS 23.7 mg Twice a Day + MMF + Corticosteroids (n=267) Placebo + MMF + Corticosteroids (n=266) Glomerular Filtration Rate Decreased 26% 9% Hypertension 19% 9% Diarrhea 19% 13% Headache 15% 8% Anemia 12% 6% Cough 11% 2% Urinary Tract Infection 10% 6% Abdominal Pain Upper 7% 2% Dyspepsia 6% 3% Alopecia 6% 3% Renal Impairment 6% 3% Abdominal Pain 5% 2% Mouth Ulceration 4% 1% Fatigue 4% 1% Tremor 3% 1% Acute Kidney Injury 3% 1% Decreased Appetite 3% 1% a LUPKYNIS Prescribing Information b AURORA 2 was a double-blind, placebo-controlled extension study of adults with active LN who completed AURORA 1 c Saxena et al., Arthritis Rheumatol 2024 Further, in AURORA 2 b, LUPKYNIS demonstrated safety comparable to that seen in AURORA 1 with no unexpected safety signals observed through 3 years a,c 16
Slide 17 — PRESERVE:
® PRESERVE: A Multi-Center Phase 4 Study of the Efficacy and Safety of LUPKYNIS in Combination with Belimumab, Obinutuzumab or Anifrolumab at Inducing Rapid Renal Response in Patients with Lupus Nephritis
Slide 18 — While LUPKYNIS Results Are the Strongest, the Majority of LN
® 0 5 10 15 20 25 30 35 ∆ 0% 32.4% 19.7% 22% 19% 24% 24% ∆ 12.7% ∆ 3% a Rovin et al., Lancet 2021. CRR = UPCR of ≤0.5 mg/mg, stable renal function (eGFR ≥60 mL/min/1.73 m2 or no confirmed decrease from baseline in eGFR of >20%), no sustained corticosteroids and no rescue medications. b Furie et al., N Engl J Med 2020. CRR = UPCR of <0.5 mg/mg, an eGFR no worse than 10% below the pre-flare value or ≥90 mL/min/1.73 m2, and no rescue medications. c Furie et al., Ann Rheum Dis 2022. CRR = UPCR of <0.5 mg/mg, normal renal function (serum creatinine ≤ULN) without worsening of baseline serum creatinine by more than 15% and inactive urinary sediment (<10 RBCs/high-power field without RBC casts) and no rescue medications. 18 While LUPKYNIS Results Are the Strongest, the Majority of LN Patients Do Not Achieve Proteinuria Control as Measured by CRR at Week 24 with Any Regimen AURORA 1 a NOBILITY c BLISS-LN b Complete Renal Response at Week 24 LUPKYNIS + MMF + Corticosteroids Placebo + MMF + Corticosteroids Belimumab + MMF or CYC/AZA + Corticosteroids Placebo + MMF or CYC/AZA + Corticosteroids Obinutuzumab + MMF + Corticosteroids Placebo + MMF + Corticosteroids Complete Renal Response, % LUPKYNIS Belimumab Obinutuzumab
Slide 19 — Complementary Mechanisms May Work in Concert to Enhance Efficacy
® Complementary Mechanisms May Work in Concert to Enhance Efficacy 19 Voclosporin Belimumab Stabilizes podocyte structure T Cell Immature B Cell Mature B Cell Plasmablast Plasma Cell Inhibits BAFF Downregulates B cells Reduces pathogenic autoantibody production by B cells B cells maintain T cell activation through ongoing antigen presentation T follicular helper cells signal the activation of B cells Inhibits: • IL-2 mediated T cell activation • IFN-γ mediated inflammatory response
Slide 20 — Complementary Mechanisms May Work in Concert to Enhance Efficacy
® Complementary Mechanisms May Work in Concert to Enhance Efficacy 20 Voclosporin Obinutuzumab Stabilizes podocyte structure T Cell Immature B Cell Mature B Cell Plasmablast Plasma Cell CD20 antigen Targets CD20 antigens Depletes immature and mature B cells Reduces pathogenic autoantibody production by B cells B cells maintain T cell activation through ongoing antigen presentation T follicular helper cells signal the activation of B cells Inhibits: • IL-2 mediated T cell activation • IFN-γ mediated inflammatory response
Slide 21 — Complementary Mechanisms May Work in Concert to Enhance Efficacy
® Complementary Mechanisms May Work in Concert to Enhance Efficacy 21 Voclosporin Anifrolumab Inhibits: • IL-2 mediated T cell activation • IFN-γ mediated inflammatory response Stabilizes podocyte structure T Cell Inhibits type 1 interferon signaling Immature B Cell Mature B Cell Plasmablast Plasma Cell Plasmacytoid dendritic cell Plasmacytoid dendritic cell Type 1 interferons Type 1 interferons T follicular helper cells signal the activation of B cells B cells maintain T cell activation through ongoing antigen presentation Downregulates plasma cell differentiation Normalizes peripheral T cell subsets Inhibits type 1 interferon signaling Anifrolumab
Slide 22 — PRESERVE Study Schema
® PRESERVE Study Schema 22 Screening Period (up to 4 weeks) a Follow-Up Period (4 weeks) • Adult (18-75 years old) • Diagnosed with SLE according to 2019 EULAR / ACR criteria • Biopsy-proven LN • UPCR ≥0.5 g/g and <5.0 g/g from a FMV urine sample • Taking or eligible to start MPAA and corticosteroids • Taking or eligible to start belimumab or anifrolumab or received at least 2 infusions of obinutuzumab Key Eligibility Criteria LUPKYNIS + Belimumab per USPI or Obinutuzumab per USPI or Anifrolumab per USPI + MPAA: MMF (or MPA equivalent dose) target dose 1 g/day b + IV methylprednisolone and oral prednisone (or equivalent) c Treatment Regimen (N=150) END OF STUDY Treatment Period (24 weeks) Primary Endpoint: • CRR at 24 weeks Key Secondary Endpoints: • Incidence of TEAEs • PRR at 24 weeks • Time to CRR • Time to PRR • Deep renal response at 24 weeks Endpoints a The Screening Period may be extended beyond 4 weeks, if necessary, to accommodate the procurement of concomitant biologic therapy (ie, belimumab, obinutuzumab or anifrolumab) or the receipt of biopsy results. The following Screening assessments must be performed within 4 weeks prior to initiating the Treatment Period (ie, Day 1): serum chemistry, pregnancy test and UPCR. b All patients (whether or not already on MPAA pre study) will receive treatment with MPAA (MMF or MPA) with a target MMF dose of 1 g/day. c All patients must receive a course of IV methylprednisolone (total dose of ≥1.0 g if body weight ≥45 kg or ≥0.5 g if body weight <45 kg) during the 3 months prior to Screening, during Screening or on Days 1 and 2. All patients will receive oral prednisone (or equivalent) at a starting dose of 25 mg/day if body weight ≥45 kg or 20 mg/day if body weight <45 kg and follow a standardized tapering schedule. 1 3 5 7 9 17 24 Taper Schedule: Oral Prednisone c Study Week 25 mg/day 20 mg/day 15 mg/day 10 mg/day 5 mg/day 2.5 mg/day
Slide 23 — Aritinercept
® Aritinercept A dual BAFF/APRIL inhibitor for the potential treatment of autoimmune diseases
Slide 24 — Aritinercept Is a Dual BAFF/APRIL Inhibitor
® Aritinercept Is a Dual BAFF/APRIL Inhibitor • Aritinercept contains a BCMA-engineered extracellular binding domain optimized for superior affinity to BAFF and APRIL (others use TACI-engineered extracellular binding domain) − BCMA has a stronger natural affinity for APRIL than TACI a • Aritinercept contains an IgG4 Fc domain with no appreciable effector function (others use IgG1 Fc domain) − IgG4 is considered the least inflammatory across the IgG subclasses, in part because it poorly activates the complement system b Engineered extracellular domain of BCMA receptor AUR200 BAFF APRIL Fc domain of IgG4 Aritinercept BAFF=B cell-activating factor; APRIL=a proliferation-inducing ligand; BCMA=B cell maturation antigen; TACI=transmembrane activator and CAML interactor; Fc=fragment crystallizable; IgG4=immunoglobulin G4 a Mathur et al., J Clin Med 2023 b Oskam et al., Front Immun 2023 24
Slide 25 — Role of BAFF and APRIL
® Role of BAFF and APRIL • BAFF and APRIL are important cytokines that regulate B cell survival and differentiation, whose targets are expressed on B cells at different stages of B cell development a • Targeting both BAFF and APRIL depletes a broader set of B cells, including plasma cells, than targeting a single cytokine • Aritinercept may prevent the activation of autoreactive B cells and reduce their numbers and associated immunoglobulins (antibodies) in the body, thereby reducing important drivers of B cell-mediated autoimmune diseases B Cell Maturation b APRIL Dependency BAFF Dependency a Mathur et al., J Clin Med 2023 b Schrezenmeier et al., J Am Soc Nephrol 2018 25
Slide 26 — Aritinercept Is a High Affinity Dual BAFF/APRIL Inhibitor a
® Aritinercept Is a High Affinity Dual BAFF/APRIL Inhibitor a Aritinercept has high binding affinity for both BAFF and APRIL as compared to other dual BAFF/APRIL inhibitors Drug (Sponsor) BAFF APRIL Kd (pM) Compared to Aritinercept Kd (pM) Compared to Aritinercept Aritinercept (Aurinia) 147 N/A 28 N/A Atacicept (Vera) 856 5.8x 54 1.9x Telitacicept (RemeGen/Vor Bio) 609 4.1x 74 2.6x a Data on file 26
Slide 27 — Aritinercept Potently Inhibits BAFF- and APRIL-Mediated
® Aritinercept Potently Inhibits BAFF- and APRIL-Mediated B Cell Proliferation a Aritinercept potently inhibits both BAFF- and APRIL-mediated B cell proliferation as compared to other dual BAFF/APRIL inhibitors Drug (Sponsor) BAFF APRIL IC50 (nM) Compared to Aritinercept IC50 (nM) Compared to Aritinercept Aritinercept (Aurinia) 0.11 N/A 0.42 N/A Atacicept (Vera) 0.37 3.4x 1.72 4.1x Telitacicept (RemeGen/Vor Bio) 1.11 10.1x 2.41 5.7x a Data on file Atacicept Telitacicept Atacicept Telitacicept Relative Luminescence Units (RLUs) Relative Luminescence Units (RLUs) B Cell Proliferation in the Presence of BAFF B Cell Proliferation in the Presence of APRIL 27 Aritinercept Aritinercept
Slide 28 — Aritinercept Single Ascending Dose (SAD) Study: Design
® Placebo n=2 5 mg SC n=6 Screening Dose Level 1 (n=8 Healthy Subjects) Screening (up to 5 weeks), In-Clinic Phase (1 week) and Out-Patient Visits (13 weeks) 28 Placebo n=2 25 mg SC n=6 Screening Dose Level 2 (n=8 Healthy Subjects) Placebo n=2 75 mg SC n=6 Screening Dose Level 3 (n=8 Healthy Subjects) Placebo n=5 150 mg SC n=16 Screening Dose Level 4 (n=21 Healthy Subjects) Placebo n=2 225 mg SC n=6 Screening Dose Level 5 (n=8 Healthy Subjects) Placebo n=2 300 mg SC n=6 Screening Dose Level 6 (n=8 Healthy Subjects) SC=subcutaneous The SAD study included an expanded cohort at 150 mg Aritinercept Single Ascending Dose (SAD) Study: Design
Slide 29 — Aritinercept SAD Study: Safety Summary
® Aritinercept SAD Study: Safety Summary • Aritinercept was well tolerated at all dose levels tested • No treatment-related Grade ≥3 adverse events a • No treatment-related serious adverse events (SAEs) a • No discontinuations due to treatment-related adverse events • Adverse events that occurred in more than one subject included: – Injection site reactions b (24% aritinercept, 13% placebo) o All injection site reactions were Grade 1 – Headache (11% aritinercept, 7% placebo) – Upper respiratory tract infection (7% aritinercept, 0% placebo) – Back pain (4% aritinercept, 0% placebo) • Anti-drug antibodies (ADAs) were detected in the majority of subjects at dose levels of 25 mg and higher – The presence of ADAs was not associated with any changes in safety, PK or PD parameters a There was one Grade ≥3 adverse event and one SAE (same event) of concussion due to motor vehicle accident reported as not treatment related b Injection site reaction includes bruising, erythema, induration, pain, pruritus, swelling and tenderness 29
Slide 30 — Aritinercept SAD Study: Single Doses of Aritinercept Led to Robust
® 0 7 14 21 28 Study Day 20% 0% -20% -40% -60% 20% 0% -20% -40% -60% 0 7 14 21 28 Mean Change from Baseline Study Day 20% 0% -20% -40% -60% Aritinercept SAD Study: Single Doses of Aritinercept Led to Robust and Long-Lasting Reductions in Immunoglobulins in Humans 30 Pharmacodynamic effects are supportive of once-monthly dosing IgA IgM IgG Mean IgA reductions of up to 48% Mean IgM reductions of up to 59% Mean IgG reductions of up to 20% 0 7 14 21 28 Study Day
Slide 31 — Effect of a Single Dose of BAFF/APRIL Inhibitors on IgA
® 20% 0% -20% -40% -60% Effect of a Single Dose of BAFF/APRIL Inhibitors on IgA 31 a The figure and table above represent cross-trial comparisons of SAD studies. No head-to-head clinical studies have been conducted. Adapted from Davies et al., Clin Trans Sci 2024 (povetacicept); Zhang et al., Clin Pharm Drug Dev 2023 (sibeprenlimab); Willen et al., Eur J Drug Metab Ph 2020 (atacicept); Xie et al., Clin Pharm Drug Dev 2022 (telitacicept). Dose levels for povetacicept, sibeprenlimab, atacicept and telitacicept represent dose levels selected by respective sponsors for Phase 3 development. Reductions in IgA a Drug (Sponsor) Mean % Change from Baseline in IgA at Day 28 a Aritinercept (Aurinia) -48% Povetacicept (Vertex) -43% Sibeprenlimab (Otsuka) -41% Atacicept (Vera) -10% Telitacicept (RemeGen/Vor Bio) 7% 0 7 14 21 28 Study Day Aritinercept (225 mg SC) Povetacicept (80 mg SC) Sibeprenlimab (400 mg SC) Atacicept (150 mg SC) Telitacicept (240 mg SC) Mean Change from Baseline
Slide 32 — Effect of a Single Dose of BAFF/APRIL Inhibitors on IgM
® Effect of a Single Dose of BAFF/APRIL Inhibitors on IgM 32 Reductions in IgM a 20% 0% -20% -40% -60% Drug (Sponsor) Mean % Change from Baseline in IgM at Day 28 a Aritinercept (Aurinia) -59% Povetacicept (Vertex) -52% Sibeprenlimab (Otsuka) -39% Atacicept (Vera) -17% Telitacicept (RemeGen/Vor Bio) 6% Mean Change from Baseline a The figure and table above represent cross-trial comparisons of SAD studies. No head-to-head clinical studies have been conducted. Adapted from Davies et al., Clin Trans Sci 2024 (povetacicept); Zhang et al., Clin Pharm Drug Dev 2023 (sibeprenlimab); Willen et al., Eur J Drug Metab Ph 2020 (atacicept); Xie et al., Clin Pharm Drug Dev 2022 (telitacicept). Dose levels for povetacicept, sibeprenlimab, atacicept and telitacicept represent dose levels selected by respective sponsors for Phase 3 development. 0 7 14 21 28 Study Day Aritinercept (225 mg SC) Povetacicept (80 mg SC) Sibeprenlimab (400 mg SC) Atacicept (150 mg SC) Telitacicept (240 mg SC)
Slide 33 — Effect of a Single Dose of BAFF/APRIL Inhibitors on IgG
® Effect of a Single Dose of BAFF/APRIL Inhibitors on IgG 33 b There was no apparent reduction in serum IgG levels following single-dose atacicept at any of the tested doses Reductions in IgG a 0 7 14 21 28 Study Day Aritinercept (225 mg SC) Povetacicept (80 mg SC) Sibeprenlimab (400 mg SC) Telitacicept (240 mg SC) 20% 0% -20% -40% -60% Drug (Sponsor) Mean % Change from Baseline in IgG at Day 28 a Aritinercept (Aurinia) -20% Povetacicept (Vertex) -19% Sibeprenlimab (Otsuka) -13% Atacicept (Vera) N/A b Telitacicept (RemeGen/Vor Bio) 7% Mean Change from Baseline a The figure and table above represent cross-trial comparisons of SAD studies. No head-to-head clinical studies have been conducted. Adapted from Davies et al., Clin Trans Sci 2024 (povetacicept); Zhang et al., Clin Pharm Drug Dev 2023 (sibeprenlimab); Willen et al., Eur J Drug Metab Ph 2020 (atacicept); Xie et al., Clin Pharm Drug Dev 2022 (telitacicept). Dose levels for povetacicept, sibeprenlimab, atacicept and telitacicept represent dose levels selected by respective sponsors for Phase 3 development.
Slide 34 — Summary and Next Steps
® Summary and Next Steps • Aritinercept was well tolerated at all dose levels tested • Single doses of aritinercept led to robust and long-lasting reductions in immunoglobulins supportive of once-monthly dosing • Aritinercept is now in clinical development for four potential indications and has therapeutic potential across a wide range of autoimmune disorders 34
Slide 35 — ®
® © Aurinia Pharmaceuticals Inc., 2026. All rights reserved. Trademarks and logos are the property of Aurinia Pharmaceuticals Inc.